Get the Stockscreener App
12.16
2.70%
0.32
Avalo Therapeutics Inc stock is traded at $12.16, with a volume of 409.91K.
It is up +2.70% in the last 24 hours and down -24.33% over the past month.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
See More
Previous Close:
$11.84
Open:
$11.93
24h Volume:
409.91K
Relative Volume:
0.44
Market Cap:
$652.14M
Revenue:
$59,000
Net Income/Loss:
$-84.74M
P/E Ratio:
-2.0886
EPS:
-5.8222
Net Cash Flow:
$-59.69M
1W Performance:
-9.46%
1M Performance:
-24.33%
6M Performance:
-8.91%
1Y Performance:
-12.52%
1-Day Range:
$11.70
$12.35
1-Week Range:
$11.58
$13.82
52-Week Range:
$11.58
$24.27
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Name
Avalo Therapeutics Inc
Sector
Industry
Phone
410-522-8707
Address
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
12.16 | 652.14M | 59,000 | -84.74M | -59.69M | -5.8222 |
VRTX
Vertex Pharmaceuticals Inc
|
509.86 | 129.23B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.14 | 95.07B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.61 | 82.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
849.15 | 53.40B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
372.00 | 42.08B | 5.76B | 514.49M | 1.10B | 4.4813 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-06-26 | Initiated | Leerink Partners | Outperform |
| Jun-12-26 | Initiated | BofA Securities | Buy |
| Apr-09-26 | Initiated | Wolfe Research | Outperform |
| Apr-06-26 | Initiated | Citizens | Mkt Outperform |
| Feb-02-26 | Initiated | Guggenheim | Buy |
| Dec-18-25 | Initiated | Mizuho | Outperform |
| Sep-17-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-25 | Initiated | TD Cowen | Buy |
| Aug-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| Mar-25-25 | Initiated | Jefferies | Buy |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-28-25 | Initiated | Piper Sandler | Overweight |
| Feb-21-25 | Initiated | Wedbush | Outperform |
| Dec-19-24 | Initiated | BTIG Research | Buy |
| Oct-24-24 | Initiated | H.C. Wainwright | Neutral |
| Apr-16-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-24-21 | Initiated | RBC Capital Mkts | Outperform |
View All
Avalo Therapeutics Inc Stock (AVTX) Latest News
In lieu of Board fees, Avalo Therapeutics (AVTX) grants Rita Jain 1,322 fully vested stock options. - Stock Titan
1,352 fully vested options replace Board fees for Avalo Therapeutics (AVTX) director Kevin Robert Lind. - Stock Titan
In lieu of board fees, Avalo Therapeutics (AVTX) grants Ron M. Philip 1,109 stock options. - Stock Titan
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Three new hires receive options to buy Avalo shares for $15.47 each - Stock Titan
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Avalo Therapeutics CFO Christopher Sullivan Executes Option Exercise and Sells 12,394 Shares via 10b5-1 Plan - Kalkine Media
Avalo Therapeutics (AVTX) CFO sells 12K shares after option exercise - Stock Titan
AVTX 8-K FilingsAvalo Therapeutics, Inc. SEC 8-K - Stock Titan
Avalo Therapeutics (AVTX) CFO sells shares at $17.62 average, keeps 105K options - Stock Titan
Avalo Therapeutics at Cantor conference: building around il-1 beta By Investing.com - Investing.com Canada
(AVTX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Avalo Therapeutics Inc. (AVTX) Peer Comparison – Compare with Others - Value Research
Avalo Therapeutics Inc. (AVTX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Avalo Therapeutics: Phase 2 Validation Has Created An IL-1β Franchise (NASDAQ:AVTX) - Seeking Alpha
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Six new hires get options to buy 78,000 Avalo shares - Stock Titan
Avalo Therapeutics Inc. (AVTX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Avalo Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance
Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock By Investing.com - Investing.com South Africa
Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock - Investing.com
Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock By Investing.com - Investing.com Nigeria
Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock By Investing.com - Investing.com Canada
Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock By Investing.com - Investing.com India
Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock By Investing.com - Investing.com UK
Avalo Therapeutics CFO Sullivan sells over $1.4m in stock By Investing.com - Investing.com Canada
Avalo Therapeutics CFO Sullivan sells over $1.4m in stock - Investing.com
Avalo Therapeutics CFO Sullivan sells over $1.4m in stock By Investing.com - Investing.com Australia
Avalo Therapeutics (AVTX) CMO trades shares under 10b5-1 plan - Stock Titan
Avalo Therapeutics Inc. (AVTX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
How Avalo Therapeutics Inc. (AVTX) Affects Rotational Strategy Timing - Stock Traders Daily
Avalo Therapeutics chief medical officer Mittie Doyle sells $20,000 shares By Investing.com - Investing.com Nigeria
Avalo Therapeutics chief medical officer Mittie Doyle sells $20,000 shares - Investing.com India
Avalo Therapeutics CFO sells over $1.45 million in stock By Investing.com - Investing.com Nigeria
Avalo Therapeutics CFO sells over $1.45 million in stock By Investing.com - Investing.com India
Avalo Therapeutics CFO sells over $1.45 million in stock By Investing.com - Investing.com UK
Avalo Therapeutics chief medical officer Mittie Doyle sells $20,000 shares - investing.com
AVTX | Avalo Therapeutics, Inc. Common FinancialsRevenue Breakdown - quiverquant.com
Avalo Therapeutics, Inc. Revenue Breakdown – NASDAQ:AVTX - TradingView
Deep Track Capital, LP Expands Avalo Therapeutics Inc (AVTX) Sta - GuruFocus
Avalo (AVTX) Q2 2026 Earnings: The EPS Result Is Below Expectation in the Latest Session; Post-Report: Shares Move 5.28% UpRevenue Growth Outlook - vinanet.vn
Avalo Therapeutics CMO Mittie Doyle Executes Stock Option and Sells 1,000 Shares Under 10b5-1 Plan - Kalkine Media
Avalo Therapeutics (AVTX) CMO sells 1,000 shares in plan - Stock Titan
Avalo Therapeutics Insider Sold Shares Worth $1,450,419, According to a Recent SEC Filing - marketscreener.com
Avalo Therapeutics (AVTX) CFO sells 72K shares in 10b5-1 trades - Stock Titan
Avalo (AVTX) Financial Update: Profit Per Share Falls Below Its Benchmark in Latest Trading; Post-Report - vinanet.vn
Avalo Therapeutics CFO Christopher Ryan Sullivan Executes Stock Options and Sells Shares Over Two Days - Kalkine Media
Avalo Therapeutics (NASDAQ: AVTX) insider lines up new stock sale after $74K August trade - Stock Titan
Avalo Therapeutics (AVTX) insider lines up $98.7K stock sale - Stock Titan
Avalo Therapeutics Inc Stock (AVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Avalo Therapeutics Inc Stock (AVTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sullivan Christopher Ryan | Chief Financial Officer |
Sep 16 '26 |
Sale |
16.33 |
12,394 |
202,437 |
39,900 |
| Sullivan Christopher Ryan | Chief Financial Officer |
Sep 10 '26 |
Option Exercise |
8.04 |
10,185 |
81,887 |
50,085 |
| Sullivan Christopher Ryan | Chief Financial Officer |
Sep 10 '26 |
Sale |
17.62 |
10,185 |
179,457 |
39,900 |
| Doyle Mittie | Chief Medical Officer |
Aug 28 '26 |
Sale |
20.00 |
679 |
13,580 |
51,776 |
| Doyle Mittie | Chief Medical Officer |
Aug 28 '26 |
Option Exercise |
8.04 |
679 |
5,459 |
52,455 |
| Sullivan Christopher Ryan | Chief Financial Officer |
Aug 18 '26 |
Option Exercise |
9.88 |
31,031 |
306,586 |
70,931 |
| Sullivan Christopher Ryan | Chief Financial Officer |
Aug 18 '26 |
Sale |
20.05 |
31,031 |
622,324 |
39,900 |
| CHRISTOPHER RYAN SULLIVAN | Officer |
Aug 18 '26 |
Proposed Sale |
20.05 |
31,031 |
622,221 |
0 |
| CHRISTOPHER RYAN SULLIVAN | Officer |
Aug 17 '26 |
Proposed Sale |
19.59 |
70,709 |
1,385,189 |
0 |
| Sullivan Christopher Ryan | Chief Financial Officer |
Aug 17 '26 |
Option Exercise |
9.88 |
40,821 |
403,311 |
81,594 |
2.27%
3.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):